Ovid Therapeutics is pumping the brakes on a planned phase 2 trial for its ROCK2 inhibitor in a type of brain lesion while it considers any lessons to be learned from the mixed readout of ...

Genosco Inc. has divulged Rho-associated protein kinase 2 (ROCK2) inhibitors reported to be useful for the treatment of fibrosis, cancer, cardiovascular and inflammatory disorders.

Its pipeline will be led by RXC007, a selective ROCK2 inhibitor currently in a phase 2a trial in idiopathic pulmonary fibrosis (IPF), a drug in the same class as Kadmon Pharmaceuticals’ Rezurock ...

“We strongly believe in the potential of our clinical stage assets and pipeline of development candidates,” she added, pointing to lead drug RXC007, a selective ROCK2 inhibitor currently in a ...